PERKINELMER INC - PKI STOCK NEWS

PerkinElmer, a leader in health innovation, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 a.m. PT. CEO Prahlad Singh is set to discuss the company's strategic priorities. Interested parties can access a live audio webcast of the presentation via a designated page, with a replay available on PerkinElmer's Investor Relations website for 30 days post-event. The company reported revenues of approximately $5 billion in 2021 and serves customers in 190 countries.

PerkinElmer has announced FDA authorization for its EONIS™ SCID-SMA assay kit, the first-ever FDA-approved screening for spinal muscular atrophy (SMA) in newborns in the US. This in vitro diagnostic test enables simultaneous detection of SMA and severe combined immunodeficiency (SCID) using a single dried blood spot. Early detection is crucial, as both conditions can lead to severe health issues. The EONIS Platform integrates advanced PCR technology and enhances laboratory efficiency. With a proven track record, PerkinElmer aims to help save the lives of approximately 70 babies daily.

PerkinElmer (NYSE: PKI), a leading global innovator for a healthier world, will present at the 2022 Stifel Healthcare Conference on November 16, 2022, at 9:10 a.m. ET in New York, NY. Max Krakowiak, the CFO, will discuss the company's strategic priorities during a fireside chat. Interested attendees can register here. A live audio webcast will be available on the investor relations website, with a replay accessible for 90 days.

PerkinElmer reported third quarter 2022 results, revealing a GAAP EPS from continuing operations of $0.55, down from $0.94 a year ago. Revenue decreased 17% year-over-year to $712 million, with pro forma revenue at $1.03 billion, reflecting a 12% organic growth excluding COVID-related impacts. The company anticipates fourth quarter revenue of approximately $0.73 billion and full year revenue of $3.30 billion. Adjusted EPS for the quarter was $1.51, compared to $2.31 last year. Challenges persist in the Diagnostics segment, which saw a 39% decline in revenue.

Epic Sciences has appointed William J. Kullback as the new Chief Financial Officer (CFO), succeeding Joel S. Smith, who retains other executive roles. Kullback brings 27 years of experience, previously leading BioLegend's $5.25 billion acquisition by PerkinElmer (PKI). The company anticipates significant growth from the recent launch of DefineMBC™, aimed at enhancing breast cancer diagnostics, which is expected to boost operations and revenue in 2023. Kullback's expertise will be vital for scaling the organization to meet increasing demand.

The Board of Directors of PerkinElmer (NYSE: PKI) has announced a regular quarterly dividend of $0.07 per share. This dividend will be payable on February 10, 2023, to all shareholders registered by the close of business on January 20, 2023. In 2021, PerkinElmer reported revenue of approximately $5 billion and employs over 16,000 individuals worldwide. The company operates in 190 countries and is part of the S&P 500 Index.

PerkinElmer, Inc. (NYSE: PKI) will release its third quarter 2022 financial results on November 8, 2022. The management will host a webcast at 8:00 a.m. ET to discuss the results. The company anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share to exceed prior guidance. Total revenue is expected to be near the high end of prior guidance, facing headwinds from foreign exchange. The company's revenue in 2021 was approximately $5 billion, serving customers in 190 countries.

PerkinElmer has partnered with Ghana Health Services and the Sickle Cell Foundation to enhance neonatal screening for sickle cell disease (SCD) in Ghana. The goal is to increase screening from 4% to 50% by 2030, with a donation facilitating the capacity to screen an additional 50,000 babies yearly. Their scalable MigeleTM Gel Electrophoresis Systems are designed to support this initiative, enabling reliable and cost-effective screening. PerkinElmer aims to bolster sustainable healthcare solutions and educate communities about early SCD intervention.